ALLIANCES AND COLLABORATIONS (Lilly) (Details) (USD $) In Millions, unless otherwise specified	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Alliances and Collaborations Statement [Line Items]
Net sales	$ 4,191	$ 3,736	$ 4,443	$ 5,251	$ 5,454	$ 5,345	$ 5,434	$ 5,011	$ 17,621	$ 21,244	$ 19,484
Amortization expense - upfront, milestone and other licensing payments									607	353	271
Other (income)/expense									(80)	(334)	(93)
Other intangible assets - upfront, milestone and other licensing payments	8,778				3,124				8,778	3,124
Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Net sales									702	691	662
Lilly [Member]
Alliances and Collaborations Statement [Line Items]
Amount of promissory notes assumed in an acquisition that were repaid to Lilly									1,400
Lilly [Member] | Erbitux [Member]
Alliances and Collaborations Statement [Line Items]
Net sales									702	691	662
Commercialization expense reimbursements to/(from) collaboration partner									(20)	(18)	(16)
Lilly [Member] | Erbitux [Member] | North America [Member]
Alliances and Collaborations Statement [Line Items]
Distribution fee, percentage of net sales	39.00%								39.00%
Distribution fees and royalty expense									291	287	275
Lilly [Member] | necitumumab [Member]
Alliances and Collaborations Statement [Line Items]
Research and development reimbursements to/(from) collaboration partner									14	12	12
Lilly [Member] | Erbitux And Necitumumab [Member] | Upfront, milestone and other licensing payments [Member]
Alliances and Collaborations Statement [Line Items]
Amortization expense - upfront, milestone and other licensing payments									38	37	37
Other intangible assets - upfront, milestone and other licensing payments	211				249				211	249
Payment for license acquisition	500								500
Lilly [Member] | Byetta And Bydureon [Member] | Non United States [Member]
Alliances and Collaborations Statement [Line Items]
Maximum amount payable to alliance partner for losses incurred									60
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member]
Alliances and Collaborations Statement [Line Items]
Percentage share of pre-tax profit/loss received from the net sales of a collaboration partner to be shared further equally with another collaboration partner.	50.00%								50.00%
Lilly and Merck KGaA [Member] | Erbitux [Member] | Japan [Member] | Commercialization profit sharing income expense [Member]
Alliances and Collaborations Statement [Line Items]
Other (income)/expense									$ (37)	$ (34)	$ (39)